FierceBiotech Radio Podcast Episodes Online

Loading podcasts

Fetching podcast shows and categories...

Loading page

Opening Radio and Podcast...

Ready2SERAustralia · College Radio, World Music

Live--:--

FierceBiotech Radio Podcast Episodes Online | Radio and Podcast

Episodes

43 episodes

Pricing drugs, selling hype and how we got here in the first place

FierceBiotech chats with a pair of lawyers about how drug pricing is unique in the U.S. and how the biopharma environment lends itself to se...

15:46May 15, 2018

The FierceMadness drug name showdown and how do drugs get their zany names anyway?

Fierce editors discuss the 2018 FierceMadness drug name tournament, its origins, and our favorites heading into the competition, while Scott...

21:26Mar 13, 2018

Back from the dead: FierceBiotech Radio at the Battle of the Biotech Bands

FierceBiotech Radio rose from the grave for this special Halloween episode where we sat down with some of the scientists, account associates...

09:46Oct 31, 2017

GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster

Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial an...

28:41Mar 18, 2016

The FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'

Fierce editors discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes...

41:26Feb 26, 2016

Pharma's TV blitz, biotech's IPO trickle, and the M&A future of Intercept Pharmaceuticals

Fierce editors discuss the rise of TV ads for specialty drugs, signs of life in the biotech IPO scene, and the case for Intercept Pharmaceut...

39:23Feb 18, 2016

Pharma's day on the Hill, biotech's paucity of M&A, and the gathering storm of biosimilars

Fierce editors discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world...

40:30Feb 11, 2016

Gilead's wide-open future, biotech's long winter, and Sanofi's ongoing makeover

Fierce editors discuss the future of Gilead Sciences, biotech's continued slump on Wall Street, and the latest move in Sanofi's efforts to r...

36:41Feb 4, 2016

Shire's byzantine Baxalta pursuit, biotech's pragmatic winter and Valeant's CEO shakeup

Fierce editors discuss Shire's increasingly complicated ambition to acquire Baxalta, the changing climate of biotech venture capital and the...

22:37Jan 8, 2016

The burning hole in Gilead's $25B pocket and AbbVie's future in hematology

Fierce editors discuss the discussion around Gilead Sciences' huge cash reserve and the many things the company might buy. Plus, a look back...

19:52Dec 10, 2015

Gilead's maxed-out revenue, BioMarin's FDA struggles, and GSK's rock and hard place

In an episode free of Valeant Pharmaceuticals and Martin Shkreli, Fierce editors discuss a Senate investigation into Gilead Sciences' pricin...

24:31Dec 3, 2015

The ins and outs of 'Pfizergan,' whatever it is Martin Shkreli's doing and the end of two takeover battles

Fierce editors discuss the long-awaited merger agreement between Pfizer and Allergan, Martin Shkreli's CEO double duty, and the whimpering c...

28:35Nov 24, 2015

Sanofi's middling future, Amgen's $10B shopping list, and a novel pharma lawsuit

Fierce editors discuss Sanofi's uninspiring forecast, Amgen's return to high-dollar dealmaking and a lawsuit that accuses a drug company of...

32:02Nov 12, 2015

Fraud's not that big of a deal: the Valeant story, according to Bill Ackman

Fierce editors discuss the latest turns in the Valeant Pharmaceuticals saga, the seeming inevitability of a Pfizer-Allergan merger, and Shir...

29:46Nov 5, 2015

Valeant's semantic innovation, Pfizer's future and the slow trickle of biotech IPOs

Fierce editors discuss a fascinating Valeant Pharmaceuticals conference call, Pfizer's desire for a big buyout and the creaky world of biote...

25:08Oct 29, 2015

Doomsdays for Valeant, Biogen and biotech VC

Fierce editors discuss a rough day for Valeant Pharmaceuticals and Biogen, plus the changing in winds in biotech venture capital.

21:50Oct 22, 2015

Lilly's latest pipeline peril, Mylan's M&A broken record, and German Merck's big rebrand

Fierce editors discuss a major blow to Eli Lilly's late-stage pipeline, Mylan's ongoing courtship of Perrigo, and Merck KGaA's big push to d...

28:55Oct 15, 2015

Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot

Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and...

26:30Oct 8, 2015

Valeant feels the Bern, biotech buckles on Wall Street, and Bristol-Myers turns to Family Feud

Fierce editors discuss how concerns about drug pricing have affected biopharma companies large and small, the latest threat to the biotech b...

21:43Oct 1, 2015

John Carroll on Turing Pharma and Martin Shkreli

FierceBiotech's John Carroll discusses his personal experience with the ongoing fallout over Turing Pharmaceuticals' drug pricing and CEO Ma...

14:58Sep 22, 2015

Lilly and Boehringer's 'amazing' diabetes data, biotech's VC boom, and Severin Schwan's hot mic

Fierce editors discuss some surprising trial results for a diabetes drug from Eli Lilly and Boehringer Ingelheim, the continued flow of mone...

28:23Sep 18, 2015

GlaxoSmithKline's horrible, no good, very bad year; Kyle Bass' 'truthful irrelevancy'; and the return of vanity pharma websites

Fierce editors discuss the latest setback in a bad run of form for GlaxoSmithKline, Kyle Bass' trouble with drug patents, and a new twist in...

26:36Sep 11, 2015

Valeant's fantasy football M&A, the gathering PCSK9 storm, and Novartis' alarming new campaign

Fierce editors Carly Helfand and Damian Garde discuss Valeant Pharmaceuticals' latest reclamation projects, the bad-cholesterol horse race b...

28:13Sep 4, 2015

The future of 'female Viagra,' the return of Allergan buyout chatter, and an overuse of the word 'allegedly'

Fierce editors discuss the controversial FDA approval of the first libido drug for women, what Allergan should buy next, and Retrophin's law...

28:55Aug 20, 2015

Amarin's First Amendment crusade, Martin Shkreli's Twitter and Kim Kardashian's Instagram

Fierce editors discuss a court ruling that could change how pharma companies market drugs, a biotech CEO's nuanced relationship with Twitter...

31:55Aug 13, 2015

Shire's $30B gambit, Merck's '100% effective' Ebola vaccine, and GSK's latest corruption scandal

Fierce editors discuss Shire's $30 billion bid for the nascent Baxalta, the promise of Merck's vaccine for Ebola, and the latest corruption...

29:11Aug 6, 2015

Allergan's 'transformational' moves, Sanofi's new bet on Regeneron, and the (latest) biggest-ever biotech IPO

Fierce editors discuss a surprise 180 from Allergan, an unsurprising deal involving Sanofi and Regeneron, and the latest biotech IPO stirrin...

25:15Jul 30, 2015

Lilly and Biogen at #AAIC2015, the first PCSK9 approval, and selling drugs to millennials

Fierce editors discuss the latest data on some closely watched treatments for Alzheimer's disease, the latest on a new group of would-be-blo...

28:39Jul 23, 2015

Celgene's $7.2B splash, Sanofi's shakeup, and GSK's big, bad wolf

Fierce editors discuss the latest big M&A news, the future of Sanofi, Patrick Soon-Shiong's evolving biotech business and a troubling new dr...

23:21Jul 16, 2015

Novartis and Vertex score big approvals, Mylan runs into real estate controversy, and @brentlsaunders makes a splash on Twitter

Fierce editors discuss a pair of major new drug approvals, a land deal scandal involving Mylan's global headquarters, and the CEO of Allerga...

21:00Jul 9, 2015

Celgene's billion-dollar bet, the future of Zoetis, and gentrification in biotech

Fierce editors discuss the news of the week, including Celgene's major investment in Juno Therapeutics; biopharma's love of Cambridge, MA; a...

20:21Jul 1, 2015

Shopping for GSK, becoming Allergan, and turning $5M into $315M

Fierce editors discuss the news of the week, including rumors surrounding GlaxoSmithKline, the evolution of Allergan and a big-money IPO tha...

23:44Jun 22, 2015

FierceBiotech Radio at #BIO2015, Part II

In Part II of FierceBiotech's BIO 2015 special, Damian Garde takes the pulse of the conference, talking to executives from Roche, uniQure, A...

24:05Jun 19, 2015

FierceBiotech Radio at #BIO2015, Part I

In Part I of FierceBiotech Radio's BIO 2015 special, Editor-in-Chief John Carroll moderates a discussion on cancer R&D, featuring leaders fr...

01:01:54Jun 19, 2015

Teva, Mylan, biotech insider trading and the 'female Viagra' saga

Fierce editors discuss the news of the week, including the ongoing squabble between Mylan and Teva, the latest cholesterol drugs, and the de...

32:38Jun 12, 2015

FierceBiotech Radio at the Battle of the Biotech Bands

FierceBiotech Radio travels to Boston's annual Battle of the Biotech Bands to meet the clinical researchers, financial managers and software...

09:12May 28, 2015

FierceBiotech Radio with Editas Medicine's Katrine Bosley

Editas Medicine CEO Katrine Bosley joins FierceBiotech Radio to discuss gene editing, the Biogen alumni network and life in biotech's boomto...

29:56May 7, 2015

J&J's Ken Drazan on changing winds in R&D and biotech's boom

Ken Drazan, head of J&J Innovation's California outpost, discusses how the pharma giant approaches external R&D, how partnering has changed...

21:07Apr 1, 2015

Is biotech in a bubble? And which drug name will win the #FierceMadness tournament?

In this bonus episode of FierceBiotech Radio, John Carroll sits down with Bloomberg Intelligence analyst Asthika Goonewardene to discuss the...

29:14Mar 26, 2015

FierceBiotech Radio and EP Vantage on biotech's big 2014

EP Vantage's Amy Brown joins FierceBiotech Radio to talk about her retrospective look at a big year for biotech and peek ahead at what might...

25:14Mar 24, 2015

FierceBiotech Radio with Express Scripts' Steve Miller

Express Scripts Chief Medical Officer Steve Miller joins us to talk about pharma pricing wars, biosimilars and his past as a drug discoverer...

17:01Mar 10, 2015

FierceBiotech Radio with Carol Gallagher

New Enterprise Associates Partner Carol Gallagher joins us to talk about her journey from pharma to biotech to venture capital and shines a...

32:01Mar 3, 2015

FierceBiotech Radio with Michael Gilman

Padlock Therapeutics CEO Michael Gilman joins us to discuss rock and roll radio, the biotech boom and the future of drug R&D.

33:06Feb 25, 2015